1. Ask Dr Durie – Doctors’ Edition: Proteasome Inhibitors in Multiple Myeloma

2. This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

3. Ask Dr Durie – Doctors’ Edition: Proteasome Inhibitors in Multiple Myeloma: Agenda

4. Proteasome Inhibitors and MM Treatment

5. FDA-Approved Proteasome Inhibitors

6. How Are Proteasome Inhibitors Used in the Frontline Setting?

7. Proteasome Inhibitors as Initial Therapy

8. SWOG S0777: RVD vs RD

9. Components of MM Treatment

10. PETHEMA/GEM: VTD vs TD vs VBMCP/VBAD/B

11. Reducing the Incidence of Treatment-Related PN With Bortezomib

12. CyBorD in ND MM

13. Overview of Induction Regimens for Transplant-Eligible Patients With ND MM

14. Proteasome Inhibitors in Transplant-Ineligible Patients

15. VISTA: VMP vs MP in Transplant-Ineligible MM

16. ALCYONE: VMP + Daratumumab as Induction Therapy in Transplant-Ineligible MM

17. Bortezomib as Maintenance Therapy in MM

18. Alternative Proteasome Inhibitors in ND MM: Carfilzomib

19. Alternative Proteasome Inhibitors in ND MM: Ixazomib

20. Does High-Risk Disease Impact Proteasome Inhibitor-Based Therapy Selection?

21. Staging MM

22. Selecting Initial Therapy for High-Risk MM

23. EMN02/HO95: Tandem Transplants

24. KRD as Initial Treatment in ND MM

25. Maintenance Therapy for High-Risk MM

26. Phase 3 Trials of Proteasome Inhibitor-Based Therapy in R/R MM

27. How Are Proteasome Inhibitors Used in the Relapsed Setting?

28. Therapy Considerations

29. Selecting a Regimen in R/R MM

30. Recent Phase 3 Trials in R/R MM

31. Proteasome Inhibitors in Practice: R/R MM

32. What Are the Adverse Events Associated With Proteasome Inhibitors and How are They Managed?

33. Antiviral Prophylaxis

34. Peripheral Neuropathy With Proteasome Inhibitors

35. Managing Peripheral Neuropathy

36. Cardiopulmonary Issues

37. Carfilzomib in Patients With Cardiac History

38. Optimizing Communication With Patients

39. Ask Dr Durie – Doctors’ Edition: Proteasome Inhibitors in Multiple Myeloma

40. FDA-Approved Proteasome Inhibitors

41. Key Takeaways

42. Optimizing Communication With Patients

43. Abbreviations

44. Abbreviations (cont)

45. Abbreviations (cont)

46. Abbreviations (cont)

47. Abbreviations (cont)